PUBLISHER: TechNavio | PRODUCT CODE: 1911341
PUBLISHER: TechNavio | PRODUCT CODE: 1911341
Controlled Substance Market In US 2026-2030
The controlled substance market in us is forecasted to grow by USD 15566.8 mn during 2025-2030, accelerating at a CAGR of 6.6% during the forecast period. The report on the controlled substance market in us provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high prevalence of chronic diseases and an aging population, increasing diagnosis and awareness of neurological and psychiatric disorders, pharmaceutical innovation in advanced delivery systems.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2026 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 6.3% |
| CAGR | 6.6% |
| Incremental Value | $15566.8 mn |
Technavio's controlled substance market in us is segmented as below:
By Product Type
- Opioids
- Stimulants
- Depressants
- Cannabinoids drugs
By Indication
- Pain management
- Sleep disorder
- Seizure
- Others
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
Geography
- North America
- US
This study identifies the growing emphasis on abuse deterrent formulations as one of the prime reasons driving the controlled substance market in us growth during the next few years. Also, rise of telemedicine and digital health platforms for prescribing and shift towards non opioid analgesics and alternative pain management therapies will lead to sizable demand in the market.
The report on the controlled substance market in us covers the following areas:
- Controlled substance market in us sizing
- Controlled substance market in us forecast
- Controlled substance market in us industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading controlled substance market in us vendors that include AbbVie Inc., Amneal Pharmaceuticals Inc., Ampac Fine Chemicals, Aurobindo Pharma Ltd., Benuvia Operations LLC, Cambrex Corp., Chattem Chemicals Inc., Curia Global Inc., Hikma Pharmaceuticals Plc, Lannett Co Inc., Merck and Co. Inc., Noramco Inc., Pfizer Inc., Purisys LLC, Rhodes Pharmaceuticals L.P., Siegfried Holding AG, SpecGx LLC, Teva Pharmaceutical Ltd., Zealand Pharma. Also, the controlled substance market in us analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Country Market Characteristics
- Executive Summary - Chart on Market Segmentation by Product Type
- Executive Summary - Chart on Market Segmentation by Indication
- Executive Summary - Chart on Market Segmentation by Distribution Channel
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- Overview on criticality of inputs and factors of differentiation
- 2.3 Factors of disruption
- Overview on factors of disruption
- 2.4 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
3 Market Landscape
- 3.1 Market ecosystem
- Chart on Parent Market
- Data Table on - Parent Market
- 3.2 Market characteristics
- Chart on Market characteristics analysis
- 3.3 Value chain analysis
- Chart on Value chain analysis
4 Market Sizing
- 4.1 Market definition
- Data Table on Offerings of companies included in the market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2025
- 4.4 Market outlook: Forecast for 2025-2030
- Chart on US - Market size and forecast 2025-2030 ($ million)
- Data Table on US - Market size and forecast 2025-2030 ($ million)
- Chart on US: Year-over-year growth 2025-2030 (%)
- Data Table on US: Year-over-year growth 2025-2030 (%)
5 Historic Market Size
- 5.1 Controlled Substance Market in US 2020 - 2024
- Historic Market Size - Data Table on Controlled Substance Market in US 2020 - 2024 ($ million)
- 5.2 Product Type segment analysis 2020 - 2024
- Historic Market Size - Product Type Segment 2020 - 2024 ($ million)
- 5.3 Indication segment analysis 2020 - 2024
- Historic Market Size - Indication Segment 2020 - 2024 ($ million)
- 5.4 Distribution Channel segment analysis 2020 - 2024
- Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ million)
6 Qualitative Analysis
- 6.1 Impact of AI in Controlled Substance Market in US
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
- 7.7 Market condition
- Chart on Market condition - Five forces 2025 and 2030
8 Market Segmentation by Product Type
- 8.1 Market segments
- Chart on Product Type - Market share 2025-2030 (%)
- Data Table on Product Type - Market share 2025-2030 (%)
- 8.2 Comparison by Product Type
- Chart on Comparison by Product Type
- Data Table on Comparison by Product Type
- 8.3 Opioids - Market size and forecast 2025-2030
- Chart on Opioids - Market size and forecast 2025-2030 ($ million)
- Data Table on Opioids - Market size and forecast 2025-2030 ($ million)
- Chart on Opioids - Year-over-year growth 2025-2030 (%)
- Data Table on Opioids - Year-over-year growth 2025-2030 (%)
- 8.4 Stimulants - Market size and forecast 2025-2030
- Chart on Stimulants - Market size and forecast 2025-2030 ($ million)
- Data Table on Stimulants - Market size and forecast 2025-2030 ($ million)
- Chart on Stimulants - Year-over-year growth 2025-2030 (%)
- Data Table on Stimulants - Year-over-year growth 2025-2030 (%)
- 8.5 Depressants - Market size and forecast 2025-2030
- Chart on Depressants - Market size and forecast 2025-2030 ($ million)
- Data Table on Depressants - Market size and forecast 2025-2030 ($ million)
- Chart on Depressants - Year-over-year growth 2025-2030 (%)
- Data Table on Depressants - Year-over-year growth 2025-2030 (%)
- 8.6 Cannabinoids drugs - Market size and forecast 2025-2030
- Chart on Cannabinoids drugs - Market size and forecast 2025-2030 ($ million)
- Data Table on Cannabinoids drugs - Market size and forecast 2025-2030 ($ million)
- Chart on Cannabinoids drugs - Year-over-year growth 2025-2030 (%)
- Data Table on Cannabinoids drugs - Year-over-year growth 2025-2030 (%)
- 8.7 Market opportunity by Product Type
- Market opportunity by Product Type ($ million)
- Data Table on Market opportunity by Product Type ($ million)
9 Market Segmentation by Indication
- 9.1 Market segments
- Chart on Indication - Market share 2025-2030 (%)
- Data Table on Indication - Market share 2025-2030 (%)
- 9.2 Comparison by Indication
- Chart on Comparison by Indication
- Data Table on Comparison by Indication
- 9.3 Pain management - Market size and forecast 2025-2030
- Chart on Pain management - Market size and forecast 2025-2030 ($ million)
- Data Table on Pain management - Market size and forecast 2025-2030 ($ million)
- Chart on Pain management - Year-over-year growth 2025-2030 (%)
- Data Table on Pain management - Year-over-year growth 2025-2030 (%)
- 9.4 Sleep disorder - Market size and forecast 2025-2030
- Chart on Sleep disorder - Market size and forecast 2025-2030 ($ million)
- Data Table on Sleep disorder - Market size and forecast 2025-2030 ($ million)
- Chart on Sleep disorder - Year-over-year growth 2025-2030 (%)
- Data Table on Sleep disorder - Year-over-year growth 2025-2030 (%)
- 9.5 Seizure - Market size and forecast 2025-2030
- Chart on Seizure - Market size and forecast 2025-2030 ($ million)
- Data Table on Seizure - Market size and forecast 2025-2030 ($ million)
- Chart on Seizure - Year-over-year growth 2025-2030 (%)
- Data Table on Seizure - Year-over-year growth 2025-2030 (%)
- 9.6 Others - Market size and forecast 2025-2030
- Chart on Others - Market size and forecast 2025-2030 ($ million)
- Data Table on Others - Market size and forecast 2025-2030 ($ million)
- Chart on Others - Year-over-year growth 2025-2030 (%)
- Data Table on Others - Year-over-year growth 2025-2030 (%)
- 9.7 Market opportunity by Indication
- Market opportunity by Indication ($ million)
- Data Table on Market opportunity by Indication ($ million)
10 Market Segmentation by Distribution Channel
- 10.1 Market segments
- Chart on Distribution Channel - Market share 2025-2030 (%)
- Data Table on Distribution Channel - Market share 2025-2030 (%)
- 10.2 Comparison by Distribution Channel
- Chart on Comparison by Distribution Channel
- Data Table on Comparison by Distribution Channel
- 10.3 Hospital pharmacies - Market size and forecast 2025-2030
- Chart on Hospital pharmacies - Market size and forecast 2025-2030 ($ million)
- Data Table on Hospital pharmacies - Market size and forecast 2025-2030 ($ million)
- Chart on Hospital pharmacies - Year-over-year growth 2025-2030 (%)
- Data Table on Hospital pharmacies - Year-over-year growth 2025-2030 (%)
- 10.4 Retail pharmacies - Market size and forecast 2025-2030
- Chart on Retail pharmacies - Market size and forecast 2025-2030 ($ million)
- Data Table on Retail pharmacies - Market size and forecast 2025-2030 ($ million)
- Chart on Retail pharmacies - Year-over-year growth 2025-2030 (%)
- Data Table on Retail pharmacies - Year-over-year growth 2025-2030 (%)
- 10.5 Online pharmacies - Market size and forecast 2025-2030
- Chart on Online pharmacies - Market size and forecast 2025-2030 ($ million)
- Data Table on Online pharmacies - Market size and forecast 2025-2030 ($ million)
- Chart on Online pharmacies - Year-over-year growth 2025-2030 (%)
- Data Table on Online pharmacies - Year-over-year growth 2025-2030 (%)
- 10.6 Market opportunity by Distribution Channel
- Market opportunity by Distribution Channel ($ million)
- Data Table on Market opportunity by Distribution Channel ($ million)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Drivers, Challenges, and Opportunity
- 12.1 Market drivers
- High prevalence of chronic diseases and an aging population
- Increasing diagnosis and awareness of neurological and psychiatric disorders
- Pharmaceutical innovation in advanced delivery systems
- 12.2 Market challenges
- Intense regulatory scrutiny and stringent government oversight
- Public health crisis and social stigma associated with controlled substances
- Supply chain disruptions and manufacturing quota limitations
- 12.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
- 12.4 Market opportunities
- Growing emphasis on abuse deterrent formulations
- Rise of telemedicine and digital health platforms for prescribing
- Shift towards non opioid analgesics and alternative pain management therapies
13 Competitive Landscape
- 13.1 Overview
- 13.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 13.3 Landscape disruption
- Overview on factors of disruption
- 13.4 Industry risks
- Impact of key risks on business
14 Competitive Analysis
- 14.1 Companies profiled
- Companies covered
- 14.2 Company ranking index
- Company ranking index
- 14.3 Market positioning of companies
- Matrix on companies position and classification
- 14.4 AbbVie Inc.
- AbbVie Inc. - Overview
- AbbVie Inc. - Product / Service
- AbbVie Inc. - Key news
- AbbVie Inc. - Key offerings
- SWOT
- 14.5 Amneal Pharmaceuticals Inc.
- Amneal Pharmaceuticals Inc. - Overview
- Amneal Pharmaceuticals Inc. - Business segments
- Amneal Pharmaceuticals Inc. - Key news
- Amneal Pharmaceuticals Inc. - Key offerings
- Amneal Pharmaceuticals Inc. - Segment focus
- SWOT
- 14.6 Aurobindo Pharma Ltd.
- Aurobindo Pharma Ltd. - Overview
- Aurobindo Pharma Ltd. - Product / Service
- Aurobindo Pharma Ltd. - Key offerings
- SWOT
- 14.7 Benuvia Operations LLC
- Benuvia Operations LLC - Overview
- Benuvia Operations LLC - Product / Service
- Benuvia Operations LLC - Key offerings
- SWOT
- 14.8 Cambrex Corp.
- Cambrex Corp. - Overview
- Cambrex Corp. - Product / Service
- Cambrex Corp. - Key offerings
- SWOT
- 14.9 Hikma Pharmaceuticals Plc
- Hikma Pharmaceuticals Plc - Overview
- Hikma Pharmaceuticals Plc - Business segments
- Hikma Pharmaceuticals Plc - Key news
- Hikma Pharmaceuticals Plc - Key offerings
- Hikma Pharmaceuticals Plc - Segment focus
- SWOT
- 14.10 Lannett Co Inc.
- Lannett Co Inc. - Overview
- Lannett Co Inc. - Product / Service
- Lannett Co Inc. - Key offerings
- SWOT
- 14.11 Merck and Co. Inc.
- Merck and Co. Inc. - Overview
- Merck and Co. Inc. - Business segments
- Merck and Co. Inc. - Key news
- Merck and Co. Inc. - Key offerings
- Merck and Co. Inc. - Segment focus
- SWOT
- 14.12 Noramco Inc.
- Noramco Inc. - Overview
- Noramco Inc. - Product / Service
- Noramco Inc. - Key offerings
- SWOT
- 14.13 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Product / Service
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- SWOT
- 14.14 Purisys LLC
- Purisys LLC - Overview
- Purisys LLC - Product / Service
- Purisys LLC - Key offerings
- SWOT
- 14.15 Rhodes Pharmaceuticals L.P.
- Rhodes Pharmaceuticals L.P. - Overview
- Rhodes Pharmaceuticals L.P. - Product / Service
- Rhodes Pharmaceuticals L.P. - Key offerings
- SWOT
- 14.16 SpecGx LLC
- SpecGx LLC - Overview
- SpecGx LLC - Product / Service
- SpecGx LLC - Key offerings
- SWOT
- 14.17 Teva Pharmaceutical Ltd.
- Teva Pharmaceutical Ltd. - Overview
- Teva Pharmaceutical Ltd. - Business segments
- Teva Pharmaceutical Ltd. - Key news
- Teva Pharmaceutical Ltd. - Key offerings
- Teva Pharmaceutical Ltd. - Segment focus
- SWOT
- 14.18 Zealand Pharma
- Zealand Pharma - Overview
- Zealand Pharma - Product / Service
- Zealand Pharma - Key offerings
- SWOT
15 Appendix
- 15.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 15.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 15.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 15.4 Research methodology
- Research methodology
- 15.5 Data procurement
- Information sources
- 15.6 Data validation
- Data validation
- 15.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 15.8 Data synthesis
- Data synthesis
- 15.9 360 degree market analysis
- 360 degree market analysis
- 15.10 List of abbreviations
- List of abbreviations
